Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CSF3R T618I CSF3R W791* |
Therapy | AZD1480 |
Indication/Tumor Type | hematologic cancer |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CSF3R T618I CSF3R W791* | hematologic cancer | predicted - resistant | AZD1480 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with AZD1480 in culture (PMID: 28031554). | 28031554 |
PubMed Id | Reference Title | Details |
---|---|---|
(28031554) | Enhanced MAPK signaling is essential for CSF3R-induced leukemia. | Full reference... |